Latest Gastroprokinetic agent Stories
The common antibiotic, amoxicillin-clavulanate, may improve small bowel function in children experiencing motility disturbances.
Modifying stomach acid levels may not be enough to treat symptoms in neonates suspected of having gastroesophageal reflux disease.
BOSTON, May 9, 2011 /PRNewswire/ -- Rhythm announced today results demonstrating that RM-131, the company's novel ghrelin agonist, was highly effective in restoring normal gastric function in animal models of delayed gastric emptying owing to a direct prokinetic effect.
Some in South Korea experience chronic gastrointestinal symptoms fairly frequently, researchers said. Researchers led by Dr. Myung-Gyu Choi of the Kangnam St.
ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will present at the Oppenheimer & Co. 19th Annual Health Care Conference in New York, NY. A live webcast of the presentation scheduled for Tuesday, November 4 at 2:40 p.m.
ARYx Therapeutics, Inc., (NASDAQ:ARYX), a biopharmaceutical company, today announced that Procter & Gamble Pharmaceuticals, Inc.
Tranzyme Pharma announces the successful results from a "Thorough QT/QTc" study of the company's lead product TZP-101, an intravenous gastrointestinal prokinetic agent currently in two Phase IIb trials for the treatment of postoperative ileus (POI) and severe gastroparesis.
Tranzyme Pharma announced today the successful completion of a Phase I, placebo-controlled, single ascending dose study of its orally administered ghrelin agonist, TZP-102. TZP-102 is the second drug candidate from Tranzyme's internal R&D efforts to reach clinical development.
- Large; stout; burly.